Determining Which DTC Patients May Benefit from Systemic Therapy
April 26th 2024Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.
Read More
Dr. Marcia Brose Discusses Lenvatinib as a New Option in DTC
February 13th 2015Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses lenvatinib as a new treatment option for patients with radioactive iodine-refractory differentiated thyroid cancer.
Read More
Dr. Brose Discusses Lenvatinib and Sorafenib in Differentiated Thyroid Cancer
November 2nd 2014Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.
Read More
Dr. Brose Describes the DECISION Trial
December 3rd 2013Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.
Read More
Dr. Brose on Recent Advances in Papillary Thyroid Cancer
November 12th 2013Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses recent advances in papillary thyroid cancer.
Read More